### Analysis

The earnings call for Amgen Inc. in the second quarter of 2012 revealed strong financial performance and a robust pipeline of innovative drugs. The company reported solid revenue and earnings per share growth, driven by the success of its established products and new launches. Management highlighted the progress of key products like Enbrel, XGEVA, Prolia, and AMG 145, which are expected to contribute significantly to future growth. The company also mentioned strategic acquisitions and partnerships that will help drive growth in emerging markets. Despite the strong performance, analysts were focused on the competitive landscape and the potential impact of new entrants like Teva's long-acting G-CSF product.

### Conclusion

Given the strong financial performance and the promising pipeline, Amgen is likely to continue its upward trajectory. The company's strategic initiatives and acquisitions in key markets will help drive growth in the coming quarters. However, the potential competition from new entrants and the need to defend its intellectual property will require constant vigilance. Overall, the stock is expected to maintain its positive momentum in the short term.

**Rating: 1**